亚甲蓝在脓毒性休克中的应用:一项回顾性队列研究
该回顾性队列研究纳入美国Premier医疗数据库1100家中心2008至2021年出院的859868例成人脓毒性休克患者(脓毒症且使用血管升压药),其中4082例(0.5%)住院期间至少接受过一剂亚甲蓝。接受亚甲蓝者倾向更年轻并接受过大手术,用药医院多为大型城市教学医院。多变量调整后,2016至2020年亚甲蓝使用低于2008年。在住院前3天内使用亚甲蓝的2507例(61.4%)中,375例(15.0%)院内死亡;样条分析提示亚甲蓝剂量与结局呈非线性关联。作者结论为亚甲蓝在脓毒性休克中罕见使用、医院间差异大且至2020年使用下降,需要随机证据评估其疗效与安全性。
要点
- 美国1100家中心2008至2021年859868例成人脓毒性休克患者中,仅4082例(0.5%)住院期间接受过至少一剂亚甲蓝。
- 接受亚甲蓝的患者倾向更年轻且接受过大手术,用药医院多为大型城市教学医院。
- 多变量调整后,2016至2020年亚甲蓝使用低于2008年。
- 住院前3天内使用亚甲蓝的2507例(61.4%)中,375例(15.0%)院内死亡。
- 样条分析提示亚甲蓝剂量与结局呈非线性关联,作者认为需要随机证据评估其疗效与安全性。
适用人群与场景
- 美国Premier医疗数据库1100家中心2008至2021年出院的成人(≥18岁)脓毒性休克患者,定义为脓毒症且使用血管升压药。
- 描述使用情况的分析纳入住院期间任何时间接受亚甲蓝的患者;剂量与结局关联分析仅纳入住院前3天内接受亚甲蓝的患者。
研究设计与关键结果
- 研究类型为回顾性队列研究,样本量859868例成人脓毒性休克患者,来自美国1100家中心,数据时段2008至2021年。
- 4082例(0.5%)来自663家医院的患者住院期间至少接受过一剂亚甲蓝。
- 住院前3天内使用亚甲蓝的2507例(61.4%)中,375例(15.0%)院内死亡。
- 多变量调整后,2016至2020年亚甲蓝使用低于2008年。
- 采用五节点限制性立方样条分析,提示亚甲蓝剂量与结局呈非线性关联。
- 接受亚甲蓝的患者倾向更年轻并接受过大手术;用药医院多为大型城市教学医院。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 作者结论:亚甲蓝在脓毒性休克中罕见使用、医院间差异大且至2020年使用下降;需要随机证据评估其疗效与安全性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究描述性地显示亚甲蓝在美国脓毒性休克中应用罕见(0.5%)、医院间差异大且至2020年使用下降,作者认为需要随机证据评估其疗效与安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To describe the epidemiology of methylene blue (MB) use in septic shock and explore the association between MB dose and hospital outcomes.
DESIGN: Retrospective cohort study.
SETTING: United States.
PATIENTS: Eight hundred fifty-nine thousand eight hundred sixty-eight adult (≥ 18 yr) patients from 1100 centers with a diagnosis of septic shock (sepsis with vasopressor administration), discharged from Premier Healthcare Database hospitals in the United States from 2008 to 2021.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We included patients who received MB at any point during hospitalization (to describe utilization), then separately focused on those who received MB within the first 3 hospital days (to examine association of dose with outcomes). The primary outcome was hospital mortality. We used mixed-effects multivariable regression models to evaluate the MB use and the association between MB dose (modeled as a five-knot restricted cubic spline) and outcomes. Among patients with septic shock, 4082 patients (0.5%) from 663 hospitals received at least one dose of MB. Patients receiving MB tended to be younger and received major surgery. Hospitals in which MB was administered were larger urban teaching hospitals. After multivariable adjustment, use of MB was lower in 2016-2020 than in 2008. Of 2507 patients (61.4%) who received MB within the first 3 days of hospitalization, 375 (15.0%) died in hospital. Our spline analysis suggests a nonlinear association between MB dosing and outcomes among patients receiving MB early in their hospitalization.
CONCLUSIONS: Use of MB in septic shock is rare in the United States, but with substantial inter-hospital variability and decreased use over time through 2020. Randomized evidence is required to evaluate the efficacy and safety of MB.
参考来源
- Fernando SM, Rochwerg B, Soliman K, et al. Methylene Blue Administration in Septic Shock: A Retrospective Cohort Study. Crit Care Med. 2025. PMID: 41171046. doi:10.1097/CCM.0000000000006934
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。